The Chemistry, Manufacturing, and Controls (CMC) module is a gating factor, requiring strict compliance with FDA guidance, and any regulatory changes could impact timing; FDA currently supports using eGFR slope as primary endpoint but ongoing submission depends on adequate funding and completion of regulatory requirements.
